Heteroresistance of Cryptococcus gattii to Fluconazole

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

We analyzed 71 clinical and environmental Cryptococcus gattii strains that had been isolated before or after the advent of azole antifungals to determine their level of heteroresistance to fluconazole (LHF). All strains of C. gattii manifested heteroresistance, with LHFs that ranged between 4 microg/ml and 32 microg/ml. A considerably higher proportion of the C. gattii strains (86%) than Cryptococcus neoformans strains (46%) exhibited LHFs that were > or =16 microg/ml. No significant correlation was observed between the molecular type or serotypes of strains and their respective LHF. The strains which expressed a higher LHF were also more resistant to xenobiotics than the strains with a low LHF, and the level of resistance to xenobiotics was significantly higher than that reported for C. neoformans. The heteroresistant subpopulation, whose level of drug resistance had been raised in a stepwise manner to 64 microg/ml, reverted to the original LHF upon daily transfers in drug-free medium. Importantly, the strains with high LHFs were significantly more virulent than those with low LHFs. Since all the clinical isolates that had not been exposed to azole drugs as well as the environmental strains manifested heteroresistance to fluconazole, heteroresistance of C. gattii to azoles is an intrinsic mechanism as in C. neoformans and is associated with the strain's virulence.

Knowledge Graph

Similar Paper

Heteroresistance of Cryptococcus gattii to Fluconazole
Antimicrobial Agents and Chemotherapy 2010.0
Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans
Antimicrobial Agents and Chemotherapy 2009.0
Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro
European Journal of Medicinal Chemistry 2015.0
Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans
Antimicrobial Agents and Chemotherapy 2007.0
Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against Cryptococcus Species
Journal of Medicinal Chemistry 2022.0
Avian Aspergillus fumigatus Strains Resistant to both Itraconazole and Voriconazole
Antimicrobial Agents and Chemotherapy 2009.0
Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus
Antimicrobial Agents and Chemotherapy 2008.0
Cross-Resistance to Medical and Agricultural Azole Drugs in Yeasts from the Oropharynx of Human Immunodeficiency Virus Patients and from Environmental Bavarian Vine Grapes
Antimicrobial Agents and Chemotherapy 2007.0
Correlation between Azole Susceptibilities, Genotypes, and ERG11 Mutations in Candida albicans Isolates Associated with Vulvovaginal Candidiasis in China
Antimicrobial Agents and Chemotherapy 2010.0
Molecular Mechanism of Flucytosine Resistance in Candida lusitaniae : Contribution of the FCY2 , FCY1 , and FUR1 Genes to 5-Fluorouracil and Fluconazole Cross-Resistance
Antimicrobial Agents and Chemotherapy 2007.0